Bioburden control for glass components means limiting and measuring the viable microorganisms on a part before it is sterilised or used. It rests on four things: a clean, documented manufacturing route, validated cleaning, protective handling and packaging, and a bioburden test method that follows ISO 11737-1. This guide sets out what to specify, what to document and how to write it into a purchase specification, so that your glass arrives ready for your own validation.
TL;DR
- Bioburden is the number and type of viable microorganisms on an item. It is not the same as biofilm, and it is measured with a validated method, not by eye.
- Contamination enters through raw materials, people and packaging, so control has to cover the whole route from cutting to the sealed pack.
- EU GMP Annex 1 (2022) expects component cleaning to be validated for particles, endotoxin and bioburden. ISO 11737-1 governs how bioburden is counted.
- Put cleaning, packing, traceability and test-method requirements in the RFQ, with batch-level records you can audit.
- We make custom glass components under ISO 9001 with batch-level traceability, and we work to your cleanliness and packaging specification.
Table of Contents
- What bioburden means on a glass component
- Where contamination enters
- Controls that reduce bioburden on glass parts
- How bioburden is tested
- Sterilisation and depyrogenation of glass
- Surface choices: coatings and antimicrobial options
- What to put in the RFQ
- Our perspective
- Talk to us about your glass components
- FAQ
- Sources
What bioburden means on a glass component
The CDC glossary defines bioburden as the number and types of viable microorganisms with which an item is contaminated. It defines biofilm as an accumulated mass of bacteria and extracellular material that adheres tightly to a surface and cannot easily be removed.
The two terms matter differently on a glass part:
- Bioburden is a count at a point in time. You measure it, set an action limit and trend it batch by batch.
- Biofilm is a growth structure. It needs moisture, nutrients and time, so it is a use-phase and storage-phase concern more than a factory-floor one.
Glass is a good starting point. In a 2016 comparison of six biomedical materials, glass was the least favourable surface for Acinetobacter baumannii biofilm formation, with a mean biomass of 0.04 μm³/μm², against 2.70 μm³/μm² for polycarbonate. A smooth, non-porous, chemically stable surface is easier to clean and easier to keep clean. That advantage holds only if the part is not recontaminated on its way to you.
Where contamination enters
For bioburden in general, Sigma-Aldrich names three entry routes: raw materials, the workforce in the manufacturing environment, and packaging of the end product. Applied to a glass component, that gives a practical map.
| Stage | Typical contamination route | Control to specify |
|---|---|---|
| Raw sheet, blanks, tube | Dust and handling on receipt, interleaving material | Incoming inspection, controlled storage, clean interleaving |
| Cutting and CNC machining | Coolant, swarf, operator contact | Controlled coolants, defined handling, cleaning after each stage |
| Edge finishing and grinding | Slurry residue, abrasive carry-over | Rinse and clean steps with recorded parameters |
| Coating, printing, toughening | Fixtures, racks, furnace loading | Clean fixtures, documented loading, inspection after process |
| Final cleaning | Water quality, drying, transfer | Validated cleaning process, defined rinse and drying |
| Packing and storage | Open handling, packaging materials, time | Defined packaging, sealed packs, storage limits |
The common thread is transfer. EU GMP Annex 1 (2022) identifies the transfer of equipment and materials into and out of cleanrooms and critical zones as a major potential source of contamination. It says activities that could compromise cleanliness should be assessed and, if they cannot be eliminated, appropriately controlled. Every time a glass part moves between stations, trays or rooms, you have a point to control.
Controls that reduce bioburden on glass parts
Glass manufacture involves high temperatures, grinding, polishing and washing. None of these steps replaces a defined bioburden strategy, but together they give a good base. What decides the final count is what happens after the last forming or finishing step.
Validated cleaning
Annex 1 (Section 8.2) says primary packaging containers and components should be cleaned using validated processes, so that particle, endotoxin or pyrogen, and bioburden contamination are appropriately controlled. For a buyer, “validated” means the cleaning method has defined parameters (chemistry, temperature, time, rinse quality) and the results are repeatable across batches.
When you write the specification, state:
- The residue and particle limits that apply to the finished part.
- Whether the part is for a primary-contact application or an enclosure, window or cover.
- Which cleaning chemistries are acceptable, given your coatings, ceramic print and adhesives.
- Whether the cleaning record must travel with the batch documentation.
Handling after cleaning
The 2007 version of Annex 1 is blunt on this point. Paragraph 77 requires components, containers and equipment to be handled after final cleaning so that they are not recontaminated. Paragraph 78 says the interval between washing and drying, and between sterilisation and use, should be minimised and subject to a time limit suited to the storage conditions.
In practice this turns into specification lines such as gloved handling only, no bare-hand contact after final clean, and a maximum hold time between cleaning and packing. These are easy to write and easy to audit.
Packaging
Packaging is both a barrier and a risk. Your specification should define the pack format (single-part pouch, tray, interleaved stack), the material, and the closure. It should also say whether the pack is the sterile barrier for your downstream process or is removed before your own cleaning. The decision shapes how bioburden is later sampled, as the next section explains.
Traceability
A bioburden result is only useful if it can be tied to a batch, a process route and a date. We operate with batch-level traceability, so a result, a cleaning record and an inspection record can be linked to the same lot. That is what makes trending possible and a deviation investigable.
How bioburden is tested
ISO 11737-1:2018 gives requirements and guidance for enumerating and characterising viable microorganisms on or in health-care products, components, raw materials or packages. The methods include neutralisation, microorganism removal, culturing and enumeration. The standard also expects the method’s suitability and recovery efficiency to be validated, so that you know how much of the true population your test actually recovers.
For UK and EU medical device work, the European adoption, EN ISO 11737-1:2018/A1:2021, covers the microbial population present on health-care products before sterilisation. It maps its clauses to the General Safety and Performance Requirements of the EU MDR 2017/745 and IVDR 2017/746. If your product is sold in both markets, this is the version your technical file is likely to cite.
Sampling the part or the pack
Annex A of ISO 11737-1 says a product should be contained in its usual packaging when sampled. It adds that it is typically sufficient to determine bioburden on the product after removal from its packaging, omitting the packaging from the determination. Agree this with your laboratory before the first lot ships, because it decides how parts must be packed for sampling.
Frequency and limits
The 2007 Annex 1 states in paragraph 80 that bioburden should be monitored before sterilisation, with working limits on contamination immediately before sterilisation related to the efficiency of the sterilisation method. It also says bioburden assay should be performed on each batch for both aseptically filled and terminally sterilised products.
A 2025 article in the PDA Letter gives reference points for primary packaging. It reports that gamma irradiation by the ISO 11137 VDmax25 method has a maximum bioburden action limit of 1,000 CFU per product unit. It also reports that the EMA guideline on sterilisation of primary containers recommends 100 CFU per 100 mL before steam sterilisation cycles, including overkill cycles. The same article notes that Annex 1 Section 2.1 requires packaging materials to be controlled and tested so that bioburden and endotoxin or pyrogen levels are suitable, and that the sterility assurance level should be no greater than one in one million (10⁻⁶).
These figures belong to specific sterilisation routes and product types. Your action limit comes from your own sterilisation validation and risk assessment, not from a general table. What we can do is manufacture and document to the limit you set.
Sterilisation and depyrogenation of glass
Glass tolerates heat that would destroy polymers, which gives you options. Dry heat is the usual route for glassware. A 2024 academic review of reusable glassware notes that dry heat sterilises glassware and destroys endotoxins more effectively than moist heat, with recommended temperatures for sterilisation and depyrogenation between 160°C and 250°C, longer times being needed at lower temperatures.
For depyrogenation specifically, Cleanroom Technology reports that 250°C for 30 minutes is typically applied to reduce endotoxin by a factor of 1,000 (3 log₁₀). It adds that validation evaluates the heating characteristics of the load and the cycle, and that endotoxin-challenged articles should show at least a 3-log₁₀ reduction. West Pharma notes that the USP and Ph. Eur. recommend at least 250°C for at least 30 minutes.
What should a buyer verify before specifying a heat step?
- Thermal compatibility of the whole part. Ceramic print, coatings and bonded elements each have their own temperature limits. State the cycle in the RFQ so the process route is designed around it.
- Stress state. Toughened and chemically strengthened glass respond differently to heat. Our guides on toughened glass and chemically strengthened glass explain the trade-offs for engineers.
- Where the cycle sits. Decide whether sterilisation happens at your site, at a contractor, or after assembly. This sets the bioburden you need on the incoming glass.
Surface choices: coatings and antimicrobial options
Anti-reflective and anti-glare coatings, ceramic printing and chemical strengthening all change the surface your cleaning process meets. Specify the finish first, then confirm the cleaning chemistry against it.
Microorganisms can persist on glass. A 2026 study from the Medical University of Graz found that bacteria, fungi and bacteriophages persisted on glass from at least two days to several weeks. The practical reading for a buyer is that a disciplined cleaning, handling and storage regime is what keeps a clean part clean, and a documented surface treatment is a complement to it. For the properties and uses of antimicrobial glass, see our guide to antimicrobial glass.
What to put in the RFQ
A specification that covers bioburden is short. These are the lines we suggest including:
- Application and contact type. Patient-contact, enclosure, optical window, display cover or instrument component.
- Standards referenced. ISO 11737-1 for bioburden determination, and ISO 10993 where biological evaluation applies. Our article on ISO 10993 actions for medical device makers covers the audit side, and our biocompatible glass QA guide covers material and process checks.
- Quality system. If you need a medical device quality management system from a supplier, our note on ISO 13485 for glass suppliers sets out what UK buyers should check. For general standards, see our quality standards guide.
- Cleaning requirements. Residue limits, permitted chemistries, and whether the cleaning record ships with the batch.
- Handling and packaging. Gloved handling, pack format, closure, maximum hold time before packing.
- Test plan. Who tests, which method, how many parts per lot, and whether the part is sampled in or out of its pack.
- Traceability. Batch identification linked to process, inspection and cleaning records.
- Material choice. Glass type and grade for the application, covered in our guide to medical glass types for procurement.
The earlier these are fixed, the less rework you face at validation. Late changes to cleaning or packing often mean repeating bioburden method validation.
Our perspective
We see bioburden as a process-design question, not a test result at the end. By the time a count is taken, the opportunity to control it has passed, so we work backwards from the count you need.
That is why our emphasis is on a documented route. We operate under ISO 9001, we keep batch-level traceability, and we apply advanced inspection to finished parts. For a regulated buyer, those three things turn a good batch into an auditable one: you can follow the part from blank to pack and show an auditor how it got there.
Our range is also suited to the way medical and scientific teams work. We machine, edge-finish, coat and print glass to tight tolerances, and we scale from prototype to volume. A cleanliness requirement agreed at the prototype stage carries through to production, so the part you validated is the part you receive.
Our advice to engineering and procurement teams is to bring us the specification early, including the cleaning, packing and test requirements, and to treat them as design inputs alongside tolerance and finish. We will build the route around them.
Alexandra
Talk to us about your glass components
We supply custom glass components for medical devices, defence, aerospace, automotive displays, lighting and electronic instruments. That includes optical windows, display glass, sensor windows, CNC-machined technical glass, protective and chemically strengthened glass, ceramic printing and advanced coatings.
If you have a drawing and a cleanliness or packaging requirement, send them with your RFQ and we will review the route with you. See our glass services for the full range, or read how our glass production process runs from design to delivery.
For optical parts such as lenses, filters and beam splitters, see our optical components range. For machined parts, our CNC glass machining page explains what we need in an RFQ.
FAQ
What is the difference between bioburden and sterility?
Bioburden is the count of viable microorganisms on an item before sterilisation. Sterility is the state after a validated sterilisation process, expressed as a sterility assurance level, commonly no greater than one in one million (10⁻⁶) for products intended to be sterile. A lower starting bioburden gives your sterilisation process a smaller challenge.
Which standard governs bioburden testing for glass components?
ISO 11737-1:2018 sets out how to enumerate and characterise viable microorganisms on health-care products, components, raw materials or packages. In Europe it is adopted as EN ISO 11737-1, with a 2021 amendment linking it to the MDR and IVDR requirements. Your laboratory should validate recovery efficiency for the specific glass and finish.
Should bioburden be tested on the part or on its packaging?
ISO 11737-1 Annex A says the product should be contained in its usual packaging when sampled. It adds that it is typically sufficient to test the product after removing it from the pack, leaving the packaging out of the determination. Agree the approach with your test laboratory and state it in the specification.
Does heat treatment remove the need for bioburden control?
No. Dry heat at 160°C to 250°C is widely used for glassware, and 250°C for 30 minutes is typical for depyrogenation, but the cycle must be validated for your load. Keeping incoming bioburden low and controlled gives that validation a stable starting point and helps you meet batch-by-batch monitoring expectations.
What should I send with an RFQ for glass that needs low bioburden?
Send the drawing, the glass type, the finish and coating requirements, the contact type, the standards you work to, and your cleaning, packing and sampling requirements. Include any heat cycle the part will see later. With these in hand we can plan the route and the batch documentation from the first quote.
Sources
- CDC Infection Control glossary
- Sigma-Aldrich, Bioburden Testing
- EU GMP Annex 1 (2022)
- EU GMP Annex 1 (2007 version)
- ISO 11737-1:2018
- EN ISO 11737-1:2018/A1:2021
- ISO 11737-1:2018 Annex A, sampling
- PDA Letter, Bioburden Monitoring for Primary-Packaging Sterile Manufacturing
- Cleanroom Technology, Endotoxin control in depyrogenation tunnels
- Frontiers in Sustainability, Reusable glassware for routine cell culture
- West Pharma, Glass Packaging FAQs Part 2
- Greene et al., Acinetobacter baumannii biofilm on biomedical materials
- Pölzl et al., Assessing non-porous antimicrobial surfaces
